BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen C, Johnston T, Jeon H, Gedaly R, Mchugh P, Ranjan D. Cyclosporine Promotes Epstein-Barr Virus-Infected Human B-Cell Transformation Assayed by Three Correlated Assay Methods. Transplantation Proceedings 2009;41:366-70. [DOI: 10.1016/j.transproceed.2008.10.085] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Kosowicz JG, Lee J, Peiffer B, Guo Z, Chen J, Liao G, Hayward SD, Liu JO, Ambinder RF. Drug Modulators of B Cell Signaling Pathways and Epstein-Barr Virus Lytic Activation. J Virol 2017;91:e00747-17. [PMID: 28566383 DOI: 10.1128/JVI.00747-17] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
2 Russano de Paiva G, Adolfo da Silva N, March M, Brousset P, Laurent C. High frequency of Epstein-Barr virus–infected lymphocytes in pilonidal cysts. Human Pathology 2012;43:2241-6. [DOI: 10.1016/j.humpath.2012.03.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
3 Dojcinov SD, Venkataraman G, Raffeld M, Pittaluga S, Jaffe ES. EBV positive mucocutaneous ulcer--a study of 26 cases associated with various sources of immunosuppression. Am J Surg Pathol. 2010;34:405-417. [PMID: 20154586 DOI: 10.1097/pas.0b013e3181cf8622] [Cited by in Crossref: 342] [Cited by in F6Publishing: 107] [Article Influence: 28.5] [Reference Citation Analysis]
4 Brennan DC, Aguado JM, Potena L, Jardine AG, Legendre C, Säemann MD, Mueller NJ, Merville P, Emery V, Nashan B. Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms. Rev Med Virol 2013;23:97-125. [PMID: 23165654 DOI: 10.1002/rmv.1733] [Cited by in Crossref: 52] [Cited by in F6Publishing: 41] [Article Influence: 5.2] [Reference Citation Analysis]
5 Syeda MM, Upadhyay K, Loke J, Pearlman A, Klugman S, Shao Y, Ostrer H. Prediction of breast cancer risk based on flow-variant analysis of circulating peripheral blood B cells. Genet Med 2017;19:1071-7. [PMID: 28301456 DOI: 10.1038/gim.2016.222] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
6 Kanemitsu M, John D, Lim A, Jaffe ES, Aoki J. Clonal Epstein-Barr virus-positive mucocutaneous ulcer mimicking a mature B-cell lymphoma in a patient with mycophenolate-induced immune suppression. Leuk Lymphoma 2015;56:1908-10. [PMID: 25379620 DOI: 10.3109/10428194.2014.982646] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
7 Nagata K, Nakayama Y, Higaki K, Ochi M, Kanai K, Matsushita M, Kuwamoto S, Kato M, Murakami I, Iwasaki T, Nanba E, Kimura H, Hayashi K. Reactivation of persistent Epstein-Barr virus (EBV) causes secretion of thyrotropin receptor antibodies (TRAbs) in EBV-infected B lymphocytes with TRAbs on their surface. Autoimmunity 2015;48:328-35. [PMID: 25759125 DOI: 10.3109/08916934.2015.1022163] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
8 Sadreddini S, Jadidi-niaragh F, Younesi V, Pourlak T, Afkham A, Shokri F, Yousefi M. Evaluation of EBV transformation of human memory B-cells isolated by FACS and MACS techniques. Journal of Immunotoxicology 2016;13:490-7. [DOI: 10.3109/1547691x.2015.1132288] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
9 Núñez-Álvarez CA, Hernández-Ramírez DF, Martinez-Castillo A, Pascual Ramos V, Cabiedes J, Ortega A, Cabral AR. Cellular immune response to β2-glycoprotein-I valine/leucine247 phenotypes in Mexican patients with primary antiphospholipid syndrome. Hum Immunol 2017;78:146-52. [PMID: 28038927 DOI: 10.1016/j.humimm.2016.12.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
10 Lamos C, Dippel E. [Aggressive primary cutaneous B-cell lymphomas and novel EBV+ entities]. Hautarzt 2017;68:727-39. [PMID: 28815289 DOI: 10.1007/s00105-017-4018-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
11 Ryan C, Amor KT, Menter A. The use of cyclosporine in dermatology: part II. J Am Acad Dermatol 2010;63:949-72; quiz 973-4. [PMID: 21093660 DOI: 10.1016/j.jaad.2010.02.062] [Cited by in Crossref: 61] [Cited by in F6Publishing: 42] [Article Influence: 5.1] [Reference Citation Analysis]